Synlogic Inc. tucked a $29.4 million series A into its belt as it aims at the nexus of synthetic biology and the microbiome with the development of therapeutic microbes. Atlas Venture and New Enterprise Associates led the round, which will enable Cambridge, Mass.-based Synlogic to build out its microbial engineering platform and advance its preclinical pipeline through clinical proof of concept in several applications.